Post Traumatic Stress Drug Candidate Gets Breakthrough Therapy Status


Tonix pharmaceutical has received a breakthrough therapy designation for a drug candidate meant to treat post-traumatic stress disorder.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to a drug candidate for post-traumatic stress disorder (PTSD).

The product is cyclobenzaprine HCl sublingual tablets, known as TNX-102 SL, the product is made by Tonix Pharmaceuticals. According to the drug company, the approval was granted on the basis of a phase 2 study known as AtEase in subjects who have PTSD associated with their military service.The trial was a 12-week, randomized controlled study.

A phase 3 study will begin in the first quarter of 2017, the company said.

The evidence of the phase 2 trial showed the drug "may demonstrate substantial improvement over existing therpies one or more clincally significant endpoints," the company said in a news release.

An estimated eight million people in the US have episodes of PTSD, the company said.

Current treatment is generally with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors.

Tonix Pharmaceuticals Holding Company is based in Manhattan.

Related Videos
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD
Andrew Miller, PhD: Inventor of KarXT Discusses Pivotal EMERGENT-2 Data
New Drug Application for MDMA-Assisted Therapy for PTSD Awaits FDA Approval
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Rishi Kakar, MD: EMERGENT trials, FDA Accepts Xanomeline-Trospium Application
© 2024 MJH Life Sciences

All rights reserved.